Difference between revisions of "Part:BBa K1100002:Design"
(→References) |
(→Design Notes) |
||
| Line 7: | Line 7: | ||
===Design Notes=== | ===Design Notes=== | ||
| − | + | To validate the hypothesis that ALeaderT can be a functional terminator and then quantify the dose-termination curve. | |
| − | + | ||
| − | + | ||
===Source=== | ===Source=== | ||
Latest revision as of 15:50, 27 September 2013
J23100-ALeaderT-BCD
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 7
Illegal NheI site found at 30 - 21INCOMPATIBLE WITH RFC[21]Illegal BamHI site found at 169
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
To validate the hypothesis that ALeaderT can be a functional terminator and then quantify the dose-termination curve.
Source
J23100 from Kit, AleaderT via de novo gene synthesis, BCD via PCR, mRFP from Kit.
References
Jia X, Zhang J, Sun W, et al. Riboswitch Control of Aminoglycoside Antibiotic Resistance[J]. Cell, 2013, 152(1): 68-81.
Qi L, Haurwitz R E, Shao W, et al. RNA processing enables predictable programming of gene expression[J]. Nature biotechnology, 2012, 30(10): 1002-1006.
Haurwitz R E, Jinek M, Wiedenheft B, et al. Sequence-and structure-specific RNA processing by a CRISPR endonuclease[J]. Science, 2010, 329(5997): 1355-1358.
Mutalik V K, Guimaraes J C, Cambray G, et al. Precise and reliable gene expression via standard transcription and translation initiation elements[J]. Nature methods, 2013, 10(4): 354-360.